Eden Biodesign was founded in 2000 and was acquired by Watson Pharmaceuticals, Inc. in January 2010. Eden Biodesign was previously a contract service provider and over the course of its history has provided strategic consultancy, world-class process development, cGMP manufacturing and analytical development services for every significant biopharmaceutical product technology, including complex recombinant therapeutic proteins, monoclonal antibodies and vaccines.
In order to build world-leading development experience, Eden Biodesign has developed expertise and cGMP manufacturing capabilities for all major production technologies, including mammalian cell culture and microbial fermentation.
As Watson Pharmaceuticals’ Biologics Centre of Excellence, Eden Biodesign is now focused primarily on the development of a growing portfolio of biologics products for Watson and its partners. These include biosimilars, “biobetter” products and also innovative biopharmaceuticals in the urology and women’s health fields.